We are thankful for our customers and associates and continue remaining deeply dedicated to customer service and community involvement, and being a great place to work and shop
"Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss." Published on FDA, Accessed on November 13, 2023 at Ozempic
Nutritional priorities to support GLP -1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society
Interestingly, patients receiving tirzepatide report reduced overall GI AEs (40%), nausea (17.4%), diarrhea (13.2%) and vomiting (5.7%) compared to patients on semaglutide (43%, 19.2%, 13.7%, and 8.1% respectively)
While weight loss certainly drives some reductions in inflammatory markers, GLP-1 medicines appear to do far more